WO2004108747A3 - Lektin-konjugate - Google Patents
Lektin-konjugate Download PDFInfo
- Publication number
- WO2004108747A3 WO2004108747A3 PCT/EP2004/006141 EP2004006141W WO2004108747A3 WO 2004108747 A3 WO2004108747 A3 WO 2004108747A3 EP 2004006141 W EP2004006141 W EP 2004006141W WO 2004108747 A3 WO2004108747 A3 WO 2004108747A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- unit
- lectin
- target
- seeking
- effector
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
- A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Radiology & Medical Imaging (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006508288A JP2006527182A (ja) | 2003-06-06 | 2004-06-07 | レクチン結合体 |
EP04739672A EP1635879A2 (de) | 2003-06-06 | 2004-06-07 | Lektin-konjugate |
US11/294,963 US20060251580A1 (en) | 2003-06-06 | 2005-12-06 | Lectin conjugates |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10325752A DE10325752A1 (de) | 2003-06-06 | 2003-06-06 | Lektin-Konjugate |
DE10325752.7 | 2003-06-06 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/294,963 Continuation US20060251580A1 (en) | 2003-06-06 | 2005-12-06 | Lectin conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004108747A2 WO2004108747A2 (de) | 2004-12-16 |
WO2004108747A3 true WO2004108747A3 (de) | 2005-03-24 |
Family
ID=33482652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/006141 WO2004108747A2 (de) | 2003-06-06 | 2004-06-07 | Lektin-konjugate |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060251580A1 (de) |
EP (1) | EP1635879A2 (de) |
JP (1) | JP2006527182A (de) |
DE (1) | DE10325752A1 (de) |
WO (1) | WO2004108747A2 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10329087B4 (de) * | 2003-06-27 | 2014-02-13 | Biomedical International R + D Gmbh | Antigenhaltige Mikrosphären zur Allergietherapie |
US20090208409A1 (en) * | 2008-02-15 | 2009-08-20 | The Government Of The United States Of America, As Represented By The Secretary, Dhhs | Encapsulated nanoparticles for computed tomography imaging |
US8178319B2 (en) * | 2008-05-08 | 2012-05-15 | Peter Pahlsson | Peptides and uses thereof |
JP2011079776A (ja) * | 2009-10-07 | 2011-04-21 | Doshisha | 歯周病予防剤 |
DK2526119T3 (en) | 2010-01-19 | 2018-07-30 | Harvard College | Manipulated opsonin for pathogen detection and treatment |
WO2012113733A1 (de) * | 2011-02-21 | 2012-08-30 | Johann Wolfgang Goethe-Universität, Frankfurt Am Main | Nanopartikel als mrt-kontrastmittel zur diagnostik des hepatozellulären karzinoms |
EP2952210A3 (de) * | 2011-04-07 | 2016-03-16 | Emory University | Zusammensetzungen mit saccharidbindenden teilen und verfahren zur gezielten therapie |
JP2014523914A (ja) | 2011-07-18 | 2014-09-18 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作された微生物標的化分子およびその使用 |
EP2820147B1 (de) | 2012-02-29 | 2018-08-08 | President and Fellows of Harvard College | Schnelltests auf empfindlichkeit gegen antibiotika |
WO2014144325A1 (en) | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Methods and compositions for improving detection and/or capture of a target entity |
WO2014190040A1 (en) | 2013-05-21 | 2014-11-27 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
EP3072954B1 (de) | 2013-11-18 | 2017-12-20 | Korea Research Institute of Bioscience and Biotechnology | Für sialinsäurebindung spezifisches lectin aus hericium erinaceum |
WO2015072786A1 (ko) * | 2013-11-18 | 2015-05-21 | 한국생명공학연구원 | 헬리시움 에리나슘 버섯 유래의 시알산 결합 특이적인 렉틴 |
GB201411393D0 (en) * | 2014-06-26 | 2014-08-13 | Isis Innovation | Agents and methods for determining colorectal cancer status |
WO2017024114A1 (en) | 2015-08-06 | 2017-02-09 | President And Fellows Of Harvard College | Improved microbe-binding molecules and uses thereof |
US10507252B2 (en) | 2016-03-17 | 2019-12-17 | Paul C. Lee | Nanoparticle probes and methods of making and use thereof |
US10507253B2 (en) | 2016-03-17 | 2019-12-17 | Paul C. Lee | Nanoparticle probes and methods of making and use thereof |
CN107340343B (zh) * | 2017-07-08 | 2019-08-23 | 万舒(北京)医药科技有限公司 | 测定人血浆生物样品中的DTPA-Zn的方法 |
CN107315056B (zh) * | 2017-07-08 | 2019-09-24 | 万舒(北京)医药科技有限公司 | 测定大鼠血浆生物样品中的DTPA-Ca的方法 |
WO2023053083A1 (en) | 2021-10-01 | 2023-04-06 | Unichem Laboratories Limited | Recombinant glycan binding proteins and its use |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994005203A1 (en) * | 1992-09-04 | 1994-03-17 | The General Hospital Corporation | Biocompatible polymers containing diagnostic or therapeutic moieties |
WO1996010359A1 (en) * | 1994-10-03 | 1996-04-11 | The Trustees Of The University Of Pennsylvania | Chelate complex with high conspicuity for magnetic resonance imaging |
DE10013849A1 (de) * | 1999-09-08 | 2001-03-15 | Diagnostikforschung Inst | L-Selectin-Kontrastmittel |
US6562318B1 (en) * | 1990-09-14 | 2003-05-13 | Syngenix Limited | Particular agents |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6074643A (en) * | 1993-09-09 | 2000-06-13 | Cli Oncology, Inc. | Site-directed chemotherapy of metastases |
US6139819A (en) * | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
EP0986401B1 (de) * | 1997-05-30 | 2004-02-25 | Arch Development Corporation | P-selectin translokation ins vaskulare epitheliale lumen durch ionisierende strahlung |
US6537520B1 (en) * | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
EA200200220A1 (ru) * | 1999-07-29 | 2002-08-29 | Эпикс Медикал, Инк. | Нацеливающие мультимерные визуализирующие агенты с механизмом мультилокусного связывания |
DE10135355C1 (de) * | 2001-07-20 | 2003-04-17 | Schering Ag | Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie |
DE10135356C1 (de) * | 2001-07-20 | 2003-04-17 | Schering Ag | Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen |
-
2003
- 2003-06-06 DE DE10325752A patent/DE10325752A1/de not_active Withdrawn
-
2004
- 2004-06-07 EP EP04739672A patent/EP1635879A2/de not_active Withdrawn
- 2004-06-07 JP JP2006508288A patent/JP2006527182A/ja active Pending
- 2004-06-07 WO PCT/EP2004/006141 patent/WO2004108747A2/de active Application Filing
-
2005
- 2005-12-06 US US11/294,963 patent/US20060251580A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6562318B1 (en) * | 1990-09-14 | 2003-05-13 | Syngenix Limited | Particular agents |
WO1994005203A1 (en) * | 1992-09-04 | 1994-03-17 | The General Hospital Corporation | Biocompatible polymers containing diagnostic or therapeutic moieties |
WO1996010359A1 (en) * | 1994-10-03 | 1996-04-11 | The Trustees Of The University Of Pennsylvania | Chelate complex with high conspicuity for magnetic resonance imaging |
DE10013849A1 (de) * | 1999-09-08 | 2001-03-15 | Diagnostikforschung Inst | L-Selectin-Kontrastmittel |
Non-Patent Citations (2)
Title |
---|
KOJIMA S ET AL: "COMPARISONS OF LABELING EFFICIENCY, BIOLOGICAL ACTIVITY AND BIODISTRIBUTION AMONG 125I-, 67GA-DTPA- AND 67GA-DFO-LECTINS", EUROPEAN JOURNAL OF NUCLEAR MEDICINE, BERLIN, DE, vol. 13, no. 7, 1987, pages 366 - 370, XP002054498, ISSN: 0340-6997 * |
LEE REIKO T ET AL: "A derivative of diethylenetriaminepentaacetic acid for europium labeling of proteins", BIOCONJUGATE CHEMISTRY, vol. 12, no. 6, November 2001 (2001-11-01), pages 845 - 849, XP002313021, ISSN: 1043-1802 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004108747A2 (de) | 2004-12-16 |
US20060251580A1 (en) | 2006-11-09 |
DE10325752A1 (de) | 2004-12-30 |
JP2006527182A (ja) | 2006-11-30 |
EP1635879A2 (de) | 2006-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004108747A3 (de) | Lektin-konjugate | |
WO2006132670A3 (en) | Auristatins having an aminobenzoic acid unit at the n terminus | |
WO2005065645A3 (en) | Donepezil formulations | |
EP2292248A3 (de) | Antiangiogene Verbindungen | |
WO2007024536A3 (en) | Process for preparing maytansinoid antibody conjugates | |
SI2090323T1 (sl) | Hiperrazvejeni polimerni konjugati z neencimatsko cepljivim povezovalcem | |
WO2010033240A3 (en) | Carbohydrate-based drug delivery polymers and conjugates thereof | |
WO2008082669A3 (en) | Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage | |
PT3248613T (pt) | Conjugados de ligante de fármaco e beta-glucuronida | |
AU2003288467A1 (en) | Immunoconjugates with an intracellularly-cleavable linkage | |
IL180762A0 (en) | Insulin-oligomer conjugates, formulations and uses thereof | |
WO2004091517A3 (en) | Conjugates comprising human il-18 and substitution mutants thereof | |
EP1889848B8 (de) | 6,7-ungesättigtes, 7-carbamoylsubstituiertes morphinanderivat | |
AU2003298993A1 (en) | Polymer-linker-drug conjugates for targeted drug delivery | |
AU2003217576A1 (en) | Molecular sensors by competitive activation | |
AU2003302235A8 (en) | Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof | |
AU2003294318A1 (en) | Therapeutic bioconjugates | |
EP1846737A4 (de) | Ultraschallstrahlenformungsvorrichtung | |
AU2003241279A1 (en) | Antimicrobial polymer conjugates | |
BR0103563B1 (pt) | montagem de braço oscilante. | |
PL376481A1 (en) | Conjugated hydroxyalkyl starch allergen compounds | |
WO2007079404A3 (en) | Drug-polymer conjugates | |
IL178791A (en) | 104SC Monoclonal Antibody and its History Specifically Related to CialilTrausil Carbohydrate as a Potential Antimicrobial Treatment | |
AU2002306068A1 (en) | Biodegradable, environmentally-friendly pants diaper | |
AU2003217782A1 (en) | Dna-binding polyamide drug conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006508288 Country of ref document: JP Ref document number: 11294963 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004739672 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004739672 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11294963 Country of ref document: US |